"When I look at the business, I actually see patients in my mind. I don't see numbers."
Sanofi courts AstraZeneca CEO Soriot; Teva CEO optimistic on Copaxone patent ruling; AstraZeneca scores approval of diabetes combo drug.
The country's drug ministry has identified drugs as an area for savings.
The company unveils a plan for deploying controllable nanoparticles into peoples' bodies for monitoring health conditions.
Herper writes that Sanofi—without Viehbacher—is at risk of moving too slowly in an increasingly competitive industry.
Widely used plastics such as PET will have to be replaced with more costly glass containers.
The former FDA director of medical device compliance has petitioned the agency to make oral contraceptives over-the-counter.
Sanofi CEO fired; Sovaldi sales slow; Ranbaxy CEO affirms generic Nexium rights.
The next generations will engage with the digital world in a way that could effect real change in breast cancer.
Despite the Treasury's crackdown on inversions, CEO Ian Read says they would still invert for the right deal.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.